^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BB-1705

    i
    Other names: BB-1705
    Company:
    BlissBio
    Drug class:
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    5ms
    A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=288, Recruiting, Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    Halaven (eribulin mesylate) • BB-1705
    1year
    Preclinical studies of BB-1705: An EGFR-targeting eribulin-containing ADC with an affinity optimized antibody to minimize potential toxicities to normal tissues (AACR 2023)
    Panitumumab is a fully human monoclonal antibody with extremely high affinity (KD ≈10-11 M) to the epidermal growth factor receptor (EGFR) and could mediate potent blockade to EGFR/EGF engagement. In conclusion, the pharmacological and safety profiles of BB-1705 were well established through in vitro potency testing, in vivo efficacy study and general toxicity studies. This data support BB-1705 as a potent antitumor agent to EGFR medium to high-expressing cancers and warrant further investigation of BB-1705 in human clinic trials.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR overexpression
    |
    Vectibix (panitumumab) • Halaven (eribulin mesylate) • BB-1705